Skip to main content

Table 2 Correlation between cytoplasmic REDD1 expression and clinicopathologic factors

From: Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma

Characteristic REDD1 expression Total No. χ2 P-value
Low expression No. (%) High expression No. (%)
Age
 20- 4(66.7) 2(33.3) 6   0.911*
 30- 7(70.0) 3(30.0) 10   
 40- 31(67.4) 15(32.6) 46   
 50- 42(68.9) 19(31.1) 61   
 60- 45(58.4) 32(41.6) 77   
 70- 16(64.0) 9(36.0) 25   
 80- 3(75.0) 1(25.0) 4   
Stage     20.283 < 0.001
 Stage I 27(81.8) 6(18.2) 33   
 Stage II 24(85.7) 4(14.3) 28   
 Stage III 85(62.5) 51(37.5) 136   
 Stage IV 12(37.5) 20(62.5) 32   
Histologic type      < 0.001*
 Serous carcinoma 58(46.4) 67(53.6) 125   
 Mucinous carcinoma 6(100.0) 0(0.0) 6   
 Endometrioid carcinoma 30(96.8) 1(3.2) 31   
 Clear-cell carcinoma 11(78.6) 3(21.4) 14   
 Mixed-type carcinoma 43(81.1) 10(18.9) 53   
Ascites     18.699 < 0.001
 Yes 75(54.7) 62(45.3) 137   
 No 44(72.1) 17(27.9) 61   
 Unknown 26(93.5) 2(6.5) 31   
Chemotherapy response      < 0.001*
 Responders 119(74.8) 40(25.2) 159   
 Partial responders 14(34.1) 27(65.9) 41   
 Non responders 8(42.1) 11(57.9) 19   
 NC/URa 7(70.0) 3(30.0) 10   
CA125
  < 500 38(59.4) 26(40.6) 64   0.529*
  ≥ 500 38(58.5) 27(41.5) 65   
 Unknown 72(72.0) 28(28.0) 100   
  1. *Fisher’s exact test
  2. aNC/UR: No chemotherapy or Unknown response